Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 5, 2016, Pages 1279-1290

  Zhang, Rui Xue ^a   Cai, Ping ^a   Zhang, Tian ^a   Chen, King ^a   Li, Jason ^a   Cheng, Ji ^a   Pang, K Sandy ^a   Adissu, Hibret A ^b   Rauth, Andrew M ^a   Wu, Xiao Yu ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Toronto Centre for Phenogenomics   (Canada)

Author keywords

Biodistribution; Doxorubicin combination; Pharmacokinetics; Polymer lipid nanoparticles; Ratiometric delivery

Indexed keywords

BIOCHEMISTRY; CELL DEATH; CHEMOTHERAPY; NANOPARTICLES; PHARMACOKINETICS; POLYMERS; TOXICITY;

BIODISTRIBUTIONS; COMBINATION CHEMOTHERAPY; DOXORUBICIN; FLUORESCENCE IMAGING; LIPID NANOPARTICLES; LIPOSOMAL DOXORUBICIN; RATIOMETRIC; SYSTEMIC CIRCULATION;

TUMORS;

DOXORUBICIN; DOXORUBICINOL; MITOMYCIN; NANOCARRIER; NANOPARTICLE; POLYMER LIPID HYBRID NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LIPID; POLYMER;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG METABOLISM; ELIMINATION RATE CONSTANT; FEMALE; FLUORESCENCE IMAGING; HEART; IN VIVO STUDY; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHARMACOKINETIC PARAMETERS; QUANTITATIVE ANALYSIS; SUSTAINED DRUG RELEASE; SYSTEMIC CIRCULATION; TUMOR VOLUME; TUMOR XENOGRAFT; VOLUME OF DISTRIBUTION; ANIMAL; BIOAVAILABILITY; BREAST NEOPLASMS; DRUG POTENTIATION; DRUG RESISTANCE; HUMAN; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; LIPIDS; MICE; MITOMYCIN; NANOPARTICLES; POLYMERS; TISSUE DISTRIBUTION;

EID: 84962009815     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.12.383     Document Type: Article

References (54)

1. Combination chemotherapy regimen by type of cancer. University of Utah Hospitals and Clinics, Salt Lake City, UT.: facts and comparisons Available from:. http://www.hci.utah.edu/patientdocs/hci/drugs/Chemoregimen/combocancer.html.
2. Breast cancer (invasive) treatment regimens 2015, Haymarket Media, Inc, [Available from: http://www.cancertherapyadvisor.com/breast-cancer-invasive-treatment-regimens/article/218154/].
3. Schott A.F., Hayes D.F., Dizon D.S. Systemic treatment of metastatic breast cancer in women: chemotherapy 2015, UpToDate, Inc, [Available from: http://www.uptodate.com/contents/systemic-treatment-of-metastatic-breast-cancer-in-women-chemotherapy].
4. Carrick S., Parker S., Thornton C.E., Ghersi D., Simes J., Wilcken N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2009, 2. 10.1002/14651858.CD003372.pub3.
5. Dear R.F., McGeechan K., Jenkins M.C., Barratt A., Tattersall M.H., Wilcken N. Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2013, 12. 10.1002/14651858.CD008792.pub2.
6. Cardoso F., Bedard P.L., Winer E.P., Pagani O., Senkus-Konefka E., Fallowfield L.J., et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 2009, 101(17):1174-1181.
7. Alba E., Martin M., Ramos M., Adrover E., Balil A., Jara C., et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 2004, 22(13):2587-2593.
8. Joensuu H., Holli K., Heikkinen M., Suonio E., Aro A.R., Hietanen P., et al. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 1998, 16(12):3720-3730.
9. Cancello G., Bagnardi V., Sangalli C., Montagna E., Dellapasqua S., Sporchia A., et al. Phase II study with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel with metronomic cyclophosphamide as a preoperative treatment of triple-negative breast cancer. Clin Breast Cancer 2015, [in press]. 10.1016/j.clbc.2015.03.002.
10. Masuda N., Higaki K., Takano T., Matsunami N., Morimoto T., Ohtani S., et al. A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer. Cancer Chemother Pharmacol 2014, 74(2):229-238.
11. Lee J.H., Nan A. Combination drug delivery approaches in metastatic breast cancer. J Drug Deliv 2012, 2012:1-17.
12. Batist G., Gelmon K.A., Chi K.N., Miller W.H., Chia S.K., Mayer L.D., et al. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res 2009, 15(2):692-700.
13. Batist G., Sawyer M., Gabrail N., Christiansen N., Marshall J.L., Spigel D.R., et al. A multicenter, phase II study of CPX-1 liposome injection in patients (pts) with advanced colorectal cancer (CRC). J Clin Oncol 2008, 26:15S-4108S.
14. Duan X., Xiao J., Yin Q., Zhang Z., Yu H., Mao S., et al. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano 2013, 7(7):5858-5869.
15. Mayer L.D., Harasym T.O., Tardi P.G., Harasym N.L., Shew C.R., Johnstone S.A., et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 2006, 5(7):1854-1863.
16. Shuhendler A.J., Cheung R.Y., Manias J., Connor A., Rauth A.M., Wu X.Y. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res Treat 2010, 119(2):255-269.
17. Prasad P., Cheng J., Shuhendler A., Rauth A.M., Wu X.Y. A novel nanoparticle formulation overcomes multiple types of membrane efflux pumps in human breast cancer cells. Drug Deliv Transl Res 2012, 2(2):95-105.
18. Prasad P., Shuhendler A., Cai P., Rauth A.M., Wu X.Y. Doxorubicin and mitomycin C co-loaded polymer-lipid hybrid nanoparticles inhibit growth of sensitive and multidrug resistant human mammary tumor xenografts. Cancer Lett 2013, 334(2):263-273.
19. Shuhendler A.J., Prasad P., Zhang R.X., Amini M.A., Sun M., Liu P.P., et al. Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model. Mol Pharm 2014, 11(8):2659-2674.
20. Tardi P., Johnstone S., Harasym N., Xie S., Harasym T., Zisman N., et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 2009, 33(1):129-139.
21. Shuhendler A.J., O'Brien P.J., Rauth A.M., Wu X.Y. On the synergistic effect of doxorubicin and mitomycin C against breast cancer cells. Drug Metabol Drug Interact 2007, 22(4):201-233.
22. Waterhouse D.N., Gelmon K.A., Klasa R., Chi K., Huntsman D., Ramsay E., et al. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Curr Cancer Drug Targets 2006, 6(6):455-489.
23. Cheung R.Y. A study of alternative delivery strategies and systems to enhance the therapeutic effect and cytotoxic activity of anticancer agents. Thesis 2005, University of Toronto.
24. Cheung R.Y., Rauth A.M., Ronaldson P.T., Bendayan R., Wu X.Y. In vitro toxicity to breast cancer cells of microsphere-delivered mitomycin C and its combination with doxorubicin. Eur J Pharm Biopharm 2006, 62(3):321-331.
25. Tredan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007, 99(19):1441-1454.
26. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56(2):185-229.
27. Rauth A.M., Melo T., Misra V. Bioreductive therapies: an overview of drugs and their mechanisms of action. Int J Radiat Oncol Biol Phys 1998, 42(4):755-762.
28. 2-polymer-lipid nanoparticles with tunable oxygen generation rates and tumor accumulation for cancer treatment. Adv Funct Mater 2015, 25(12):1858-1872.
29. Prasad P., Gordijo C.R., Abbasi A.Z., Maeda A., Ip A., Rauth A.M., et al. Multifunctional albumin-MnO(2) nanoparticles modulate solid tumor microenvironment by attenuating hypoxia, acidosis, vascular endothelial growth factor and enhance radiation response. ACS Nano 2014, 8(4):3202-3212.
30. Babuin L., Jaffe A.S. Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ 2005, 173(10):1191-1202.
31. Wong H.L., Bendayan R., Rauth A.M., Wu X.Y. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J Pharm Sci 2004, 93(8):1993-2008.
32. Desmettre T., Devoisselle J.M., Mordon S. Fluorescence properties and metabolic features of indocyanine green (ICG) as related to angiography. Surv Ophthalmol 2000, 45(1):15-27.
33. Food and Drug Admnistration, Center for Drug Evaluation and Research Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers 2005, U.S. Department of Health and Human Services (Pharmacology and Toxicology).
34. Blum R.H., Carter S.K. Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 1974, 80(2):249-259.
35. Gabizon A., Tzemach D., Mak L., Bronstein M., Horowitz A.T. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target 2002, 10(7):539-548.
36. Shuhendler A.J., Prasad P., Chan H.K., Gordijo C.R., Soroushian B., Kolios M., et al. Hybrid quantum dot-fatty ester stealth nanoparticles: toward clinically relevant in vivo optical imaging of deep tissue. ACS Nano 2011, 5(3):1958-1966.
37. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994, 54(4):987-992.
38. Gustafson D.L., Rastatter J.C., Colombo T., Long M.E. Doxorubicin pharmacokinetics: macromolecule binding, metabolism, and excretion in the context of a physiologic model. J Pharm Sci 2002, 91(6):1488-1501.
39. Dorr R.T. New findings in the pharmacokinetic, metabolic, and drug-resistance aspects of mitomycin C. Semin Oncol 1988, 15(3 Suppl. 4):32-41.
40. Schrijvers D. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Clin Pharmacokinet 2003, 42(9):779-791.
41. Verweij J., Stuurman M., de Vries J., Pinedo H.M. The difference in pharmacokinetics of mitomycin C, given either as a single agent or as a part of combination chemotherapy. J Cancer Res Clin Oncol 1986, 112(3):283-284.
42. Thorn C.F., Oshiro C., Marsh S., Hernandez-Boussard T., McLeod H., Klein T.E., et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 2011, 21(7):440-446.
43. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011, 63(3):131-135.
44. Bachur N.R. Cytoplasmic aldo-keto reductases: a class of drug metabolizing enzymes. Science 1976, 193(4253):595-597.
45. Heibein A.D., Guo B., Sprowl J.A., Maclean D.A., Parissenti A.M. Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization. BMC Cancer 2012, 12:381-395.
46. Menna P., Recalcati S., Cairo G., Minotti G. An introduction to the metabolic determinants of anthracycline cardiotoxicity. Cardiovasc Toxicol 2007, 7(2):80-85.
47. Charrois G.J., Allen T.M. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta 2004, 1663(1-2):167-177.
48. Li S.D., Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008, 5(4):496-504.
49. Matsunaga T., Yamane Y., Iida K., Endo S., Banno Y., El-Kabbani O., et al. Involvement of the aldo-keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms. Anticancer Drugs 2011, 22(5):402-408.
50. Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003, 42(5):419-436.
51. O'Brien M.E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004, 15(3):440-449.
52. Cui J., Li C., Guo W., Li Y., Wang C., Zhang L., et al. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?. J Control Release 2007, 118(2):204-215.
53. Mamidi R.N., Weng S., Stellar S., Wang C., Yu N., Huang T., et al. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?. Cancer Chemother Pharmacol 2010, 66(6):1173-1184.
54. Laginha K.M., Verwoert S., Charrois G.J., Allen T.M. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 2005, 11(19 Pt 1):6944-6949.